Solid State Characterization of Pharmaceuticals
August 2011, Wiley-Blackwell
This book provides an up-to-date review of the current techniques used to characterize pharmaceutical solids. Ensuring balanced, practical coverage with industrial relevance, it covers a range of key applications in the field.
The following topics are included:
- Physical properties and processes
- Intellectual guidance
- X-ray diffraction
- Spectroscopy Microscopy
- Particle sizing
- Mechanical properties
- Vapour sorption
- Thermal analysis & Calorimetry
- Polymorph prediction
- Form selection
About the Editors.
1. Introduction to the Solid State – Physical Properties and Processes (Ingvar Ymen).
1.2 Neutral Pharmaceutical Molecules.
1.3 Thermodynamics and Phase Diagrams.
1.4 Neutral Pharmaceutical Molecules in the Solid State.
1.5 Salt Formation and Acid-Base Equilibrium.6
1.6 Polymorphs, Solvates and Mixed Crystals.
1.7 Phase Transitions and Kinetics.
1.8 Screening for 'Polymorphs' (Ansolvates and Solvates).
2. X-Ray Diffraction (Chris J. Gilmore).
2.2 Generation and Properties of X-Rays.
2.3 Crystal, Lattices, Unit Cells and Symmetry.
2.4 The Interaction of X-rays with Crystals.
2.5 Collecting Intensity Data for Single Crystals.
2.6 Determining Crystal Structures.
2.7 Powder Diffraction.
2.8 Amorphous Powders.
2.9 Particle Size.
2.10 Other Radiations: Neutrons and Electrons.
3. Spectroscopic Characterization (Andrew O'Neil and Howell Edwards).
3.1 Introduction and Theory.
3.2 Electromagnetic Radiation.
3.3 Vibrational Spectroscopy.
3.4 Mid- and Near-Infrared Spectroscopy.
3.5 Near-Infrared Spectroscopy.
3.6 Raman Spectroscopy.
3.7 Chemical Imaging and Mapping Microscopy.
3.8 Nuclear Magnetic Resonance Spectroscopy.
3.9 Terahertz Pulsed Spectroscopy.
4. Thermal Analysis – Conventional Techniques (Mark Saunders and Paul Gabbott).
4.2 Differential Scanning Calorimetry (DSC).
4.3 Thermogravimetric Analysis (TGA).
4.4 Dynamic Mechanical Analysis (DMA).
4.5 Determining the Melting Behaviour of Crystalline Solids.
4.7 Solvates and Hydrates (Pseudopolymorphism).
4.8 Evolved Gas Analysis (EGA) and Simultaneous Measurements.
4.9 Amorphous Content.
4.10 Purity Determination Using DSC.
4.11 Excipient Compatibility.
5. Thermal Analysis – Dielectric Techniques (Susan Barker and Milan D. Antonijevic).
5.1 General Introduction.
5.2 Common Background to the Techniques.
5.3 Dielectric Spectroscopy.
5.4 Thermally Stimulated Current (TSC) Spectroscopy.
5.5 Overall Conclusions.
6. Isothermal Calorimetric Analysis (Andrew Hills).
6.2 Calorimetry: Principle of Measurement.
6.3 Applications of IM for Characterization of Solid-State Pharmaceuticals.
6.4 Analysis of Solid-State Form Conversions.
6.5 Analysis of Solid State Chemical Reactions.
6.6 Excipient Compatibility.
7. Calorimetric Methods – Solution Calorimetry (Simon Gaisford).
7.2 The Principles of Solution Calorimetry.
8. Vapour Sorption and Surface Analysis (Jerry Y. Y. Heng and Daryl R. Williams).
8.2 Inverse Gas Chromatography.
8.3 Dynamic Vapour Sorption.
9. Microscopy (Gary Nichols, Shen Luk and Clive Roberts).
9.2 The Microscope as an Analytical Tool.
9.3 Which Microscope to Use?
9.4 Light Microscopy.
9.5 Crystal Shape.
9.6 Particle Size.
9.7 Nonambient Light Microscopy.
9.8 Scanning Electron Microscopy.
9.9 Elemental X-Ray Microanalysis.
9.10 Atomic Force Microscopy.
9.11 Future Perspectives.
10. Particulate Analysis – Mechanical Properties (Ron J. Roberts).
10.2 Tableting/Comminution Process.
10.3 Indentation and Nanoindentation Testing.
10.4 Deformation Behaviour of Powders.
10.5 Evaluation of Deformation Behaviour and Compressibility.
10.6 Solubility Parameters (d) and Cohesive Energy Density (CED) and Mechanical Properties.
10.7 Influence of Crystal Structure on Mechanical Properties.
10.8 Polymorphism and Mechanical Properties.
11. Particulate Analysis – Particle Size (Xian-Ming Zeng).
11.2 Particle Size and Shape.
11.3 Particle Shape Analysis.
11.4 Particle Diameter.
11.5 Particle Size Distribution.
11.6 The Average Particle Size.
11.7 Particle Size Measurement.
11.8 Surface Area Measurement.
11.9 Particle Size Reduction.
11.10 Particle Size Assessment and Pharmaceutical Development.
11.11 A Case Study: Medicinal Aerosols.
11.12 Concluding Remarks.
12. Computational Polymorph Prediction (Sarah L. Price and Louise S. Price).
12.3 Are Some Crystal Structures Easier to Predict than Others?
12.4 Illustrative Examples of Crystal Energy Landscapes for Pharmaceuticals.
12.5 Property Prediction.
12.6 Future Prospects.
13. Patenting of Inventions Relating to Polymorphs (Bertrand Gellie, Claire Johnson and Thomas Weisbrod).
13.4 Inventive Step.
13.5 Sufficiency of Disclosure.
13.6 Unity of Invention.
13.7 Patenting Strategy.
14. A 'Roadmap' to Solid Form Selection (Richard Storey).
14.2 Summary of Solid-Form Screening Process.
14.3 Polymorph Screening.
Ingvar Ymén, AstraZeneca R&D, Södertälje, Sweden
- A state-of-the-art review of a crucial aspect of drug development, formulation, manufacture and quality control
- Covers a range of techniques and applications ensuring key information is available in one place, and provides a point of entry to the primary literature for those requiring more detailed data
- Chapter authors from major industrial and academic laboratories, ensuring practical coverage and industrial relevance
Do you think you've discovered an error in this book? Please check the list of errata below to see if we've already addressed the error. If not, please submit the error via our Errata Form. We will attempt to verify your error; if you're right, we will post a correction below.
: Second paragraph, above the equation. Sentence is ?The number of asymmetric units in the unit cell is denominated as Z and it is basically the number of different molecular conformations?? It should read ?The number of asymmetric units in the unit cell is denominated as Z and it includes the number of different molecular conformations??
|3rd May 2011||First 440; Total 745|
|316, line 2||Errata
On page 316, line 2, (Young et al. 2003) should read (Young et al. 2003b).
|318, Section 9.8||Errata
On page 318, Section 9.8, end of first paragraph, (Goldstein et al. 1993 and 2003) should read 1992 and 2003.
Figure 14.5 reproduced, with permission, from Dr. J. McCabe, AstraZeneca
|13th June 2011||First 440; Total 745|
Figure 14.7 reproduced, with permission, from Dr. J. McCabe, AstraZeneca
|13th June 2011||First 440; Total 745|
Solid State Characterization of Pharmaceuticals (US $240.00)
Total List Price: US $375.00
Discounted Price: US $281.25 (Save: US $93.75)